Pharming Group Full Year 2022 Earnings: EPS: US$0.021 (vs US$0.025 in FY 2021)

Pharming Group (AMS:PHARM) Full Year 2022 Results

Key Financial Results

• Revenue: US$205.6m (up 3.4% from FY 2021).

• Net income: US$13.7m (down 14% from FY 2021).

• Profit margin: 6.7% (down from 8.0% in FY 2021). The decrease in margin was driven by higher expenses.

• EPS: US$0.021 (down from US$0.025 in FY 2021).

All figures shown in the chart above are for the trailing 12 month (TTM) period

Pharming Group Earnings Insights

Looking ahead, revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 21% growth forecast for the Biotechs industry in Europe.

Performance of the market in the Netherlands.

The company's shares are down 18% from a week ago.

Risk Analysis

You still need to take note of risks, for example - Pharming Group has 1 warning sign we think you should be aware of.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Join A Paid User Research Session
You’ll receive a US$30 Amazon Gift card for 1 hour of your time while helping us build better investing tools for the individual investors like yourself. Sign up here